UPRISE (Urine Prostate Screening Integrated With MRI for Prostate Cancer Early Detection)
University of Michigan Rogel Cancer Center
Summary
This clinical trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer. MPS2 is an investigational urine-based test designed to help identify the likelihood of having aggressive prostate cancer. MPS2 testing works by measuring specific early detection biomarkers that include genetic information. This next-generation test aims to address a major challenge in prostate cancer care-detecting only the cancers that truly need treatment. Results may lead to paradigm shifts in early detection algorithms and reduce reliance on MRI and biopsy.
Eligibility
- Age range
- 50–75 years
- Sex
- Male
- Healthy volunteers
- Yes
Inclusion Criteria: * Males aged 50-75 * PSA 3-20 ng/ml within the previous 3 months * Fit to undergo all procedures listed in protocol per treating physician's discretion * No prostate biopsy in the past 4 years * No prostate MRI in the past 2 years * Able to provide written informed consent Exclusion Criteria: * Prior diagnosis of prostate cancer * Contraindication to MRI (e.g. claustrophobia, pacemaker) * Contraindication to prostate biopsy * Previous hip replacement surgery, metallic hip replacement or extensive pelvic orthopaedic metal work
Interventions
- ProcedureBiopsy Procedure
Undergo biopsy
- DeviceDiagnostic Procedure
Undergo MPS2 urine test
- OtherElectronic Health Record Review
Ancillary studies
- ProcedureMagnetic Resonance Imaging
Undergo MRI
Location
- University of Michigan Rogel Cancer CenterAnn Arbor, Michigan